Update: Chinese Pharma Enlists Synaffix’s ADC Technology for Second Drug
Update (07/01/2020): Shanghai Miracogen has expanded its pre-existing license agreement with the Dutch biotech Synaffix.…
Update (07/01/2020): Shanghai Miracogen has expanded its pre-existing license agreement with the Dutch biotech Synaffix.…
Update (09/07/2019): The Switzerland-based ADC Therapeutics has completed the final closing of a €271M ($303M)…
In recent years the oncology world has focused on using the immune system to target…
Update (29.06.2018): NBE Therapeutics has extended its Series B fundraising round by 20M CHF (€17.3M),…
ADC Therapeutics has tested its antibody-drug conjugate technology in drug-resistant cancers, yielding encouraging results. Swiss biotech…
Heidelberg Pharma is developing Antibody Targeted Amanitin Conjugates (ATACs), which combine antibody-drug conjugate technology with the…
ADC development has progressed to the fourth generation. Serial entrepreneur Ulf Grawunder told me what…
Glythera and IONTAS have partnered to develop next-generation antibody-drug conjugates that are less toxic and more potent against difficult-to-treat…
ADC Therapeutics has presented preliminary Phase I data in lymphoma patients suggesting its ADC technology…
Characterizing biologics has become an essential step for successful drug development. We connected with SCIEX…
Bicycle Therapeutics has closed a massive fundraising round, raking in £40M (€46M) from American investors to…
ADCs are overcoming the challenges of first generations and returning with a vengeance. I attended the…